The Credit Pharma diclofenac transaction was announced on the same day in September 2017 as the $4.7M capital raising.At the time I thought this deal would materialize.
It was therefore quite a shock to find that this Voveran gel look alike arrangement did not proceed.
I have recently confirmed with POH[not RM]that there were regulatory issues in China surrounding the product that did not suit Credit Pharma and hence no deal was progressed.
I take from this that the ability of POH management to get a deal over the line was never an issue.
Kens
credit pharma miss
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.001(20.0%) |
Mkt cap ! $9.507M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $408 | 154.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 61 | 90794613 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 54998583 | 13 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| AVE (ASX) Chart |